Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japanese Pharmas Agree To Lower NHI Prices When Generic Uptake Is Slow

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Manufacturers would take "certain degrees of action" to lower national health insurance listed prices if generic penetration failed to reach a certain level in the same composite group during a drug's patented period, according to an industry proposal during the latest Chuikyo pharmaceutical price expert subcommittee meeting March 18

You may also be interested in...



Frustration Drives Japan To Allow Generics Before Side Patents Expire

TOKYO - In a continuing effort to raise generic drug use, Japan's Ministry of Health, Labor and Welfare has decided to allow generic drugs to be manufactured even before brand drugs' side patents expire, the ministry's Insurance Bureau officials said

Frustration Drives Japan To Allow Generics Before Side Patents Expire

TOKYO - In a continuing effort to raise generic drug use, Japan's Ministry of Health, Labor and Welfare has decided to allow generic drugs to be manufactured even before brand drugs' side patents expire, the ministry's Insurance Bureau officials said

Daiichi Sankyo’s Infringement Lawsuits Highlight Japan’s Generic Drug Tug-Of-War

Daiichi Sankyo waged patent infringement war against generic drug makers with lawsuits registered in two Japanese district courts March 23. The antibacterial drug Cravit (levofloxacin) lies at the center of the litigation brought by Daiichi Sankyo

Related Content

UsernamePublicRestriction

Register

PL000723

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel